SCHEMBL6718244

SCHEMBL6718244

Cc1ccc(-c2noc(C(F)(F)F)c2-c2ccc(S(C)(=O)=O)c(F)c2)cc1C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.52
NR1H2 P55055 3/20 0.40
NR1H3 Q13133 3/20 0.40
S1PR1 P21453 5/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
KIF11 P52732 1/20 0.38
NOTUM Q6P988 1/20 0.37
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
PIK3CD O00329 2/20 0.35
PIK3CA P42336 2/20 0.35
PIK3CB P42338 2/20 0.35
PIK3CG P48736 2/20 0.35
TP53 P04637 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723530 0.92 PTGS2 (0.55) PTGS2NR1H2NR1H3ESR1ESR2
SCHEMBL6722824 0.92 PTGS2 (0.52) PTGS2NR1H2NR1H3ESR1ESR2
SCHEMBL6718650 0.91 PTGS2 (0.54) PTGS2NR1H2NR1H3ESR1ESR2
SCHEMBL6722685 0.91 PTGS2 (0.46) PTGS2S1PR1ESR1ESR2KIF11
SCHEMBL6721774 0.90 PTGS2 (0.47) PTGS2NR1H2NR1H3S1PR1KIF11
SCHEMBL6725389 0.89 PTGS2 (0.54) PTGS2NR1H2NR1H3ESR1ESR2
SCHEMBL6718435 0.88 PTGS2 (0.51) PTGS2NR1H2NR1H3ESR1ESR2
SCHEMBL6723348 0.88 PTGS2 (0.51) PTGS2NR1H2NR1H3ESR1ESR2
SCHEMBL6723360 0.88 PTGS2 (0.57) PTGS2NR1H2NR1H3ESR1ESR2
SCHEMBL6722830 0.87 PTGS2 (0.52) PTGS2NR1H2NR1H3ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885NR1H2 282/4885NR1H3 570/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885NR1H2 242/4885NR1H3 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.